Skip to content

iRhythm Holdings, Inc. IRTC Research and development expense

Research and development expense at other companies

Boston Scientific logo
Boston ScientificBSX
$516M+16.5%
ITG
Integer HoldingsITGR
Merit Medical Systems logo
Merit Medical SystemsMMSI
Medtronic logo
MedtronicMDT
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Revenue$199.4M+25.7%
Gross profit$141.4M+29.4%
Operating income-$16.2M+50.3%
Net income-$13.9M+54.6%
EPS (diluted)-$0.43+55.7%

Balance sheet

See full
Cash & equivalents$248.5M-35.2%
Total debt$79.0M-10.5%
Total equity$161.2M+86.0%
Total assets$1.0B+8.7%

Cash flow

See full
Operating cash flow-$26.2M-232%
CapEx$6.9M-26.7%
Free cash flow-$33.1M-91.1%

Valuation

See full
Market cap$3.62B+16.0%

Profitability

See full
Gross margin71%+1.6pp
Operating margin-5.5%-2.2pp
Net margin-7.3%-3.1pp
FCF margin2.4%

Returns & leverage

See full
Return on equity-53.1%-17.4pp
Debt / equity0.5×-0.5×
Current ratio5.2×-0.5×

Where this comes from

Reported directly by iRhythm Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: iRhythm Holdings, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about iRhythm Holdings, Inc. 's research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is iRhythm Holdings, Inc. 's research and development expense?
iRhythm Holdings, Inc. (IRTC) reported research and development expense of $21.36M in Q1 2026.
How has iRhythm Holdings, Inc. 's research and development expense changed year-over-year?
iRhythm Holdings, Inc. 's research and development expense decreased by 0.7% year-over-year, from $21.52M to $21.36M.
What is the long-term trend for iRhythm Holdings, Inc. 's research and development expense?
Over 2 years (2022 to 2025), iRhythm Holdings, Inc. 's research and development expense has grown at a 34.7% compound annual growth rate (CAGR), from $46.61M to $84.61M.